NATCO launches Brivaracetam tablets, in India, for treatment of epilepsy

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the launch of Brivaracetam tablets under brand BRECITA in India. Brivaracetam is indicated towards treatment of epilepsy.

Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy's under brand name Briviact®. NATCO's BRECITA tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of INR 25/- and INR 35/- per tablet respectively. Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.802.2 as compared to the previous close of Rs. 806.25. The total number of shares traded during the day was 21371 in over 1294 trades.

The stock hit an intraday high of Rs. 823.7 and intraday low of 796.3. The net turnover during the day was Rs. 17290831.

Source : Equity Bulls

Keywords